Emerging Role of Weight-Loss Medications Post-Bariatric Surgery in Reducing Heart Disease Risk
New research suggests that weight-loss medications like semaglutide and liraglutide may reduce cardiovascular risk in patients post-bariatric surgery, especially those not achieving optimal weight or diabetes control.
Recent research presented at the European Congress on Obesity highlights the potential cardiovascular benefits of popular weight-loss drugs, such as semaglutide and liraglutide, in adults who have undergone bariatric surgery. These medications may be particularly beneficial for individuals who do not achieve sufficient weight loss or diabetes control following surgery, by further lowering the risk of major adverse cardiovascular events (MACE) like heart attacks and strokes, as well as reducing mortality.
The observational study involved adults with obesity and type 2 diabetes but no prior cardiovascular disease, analyzing data from over 4.8 million patients covered by Clalit Health Services in Israel. Among the 822 participants (average age 58, predominantly female), those treated with GLP-1 receptor agonists (GLP-1 RAs), mainly semaglutide and liraglutide, after surgery showed a 67% lower risk of MACE or death compared to those who only had bariatric surgery.
Initially, patients started with higher weight and blood glucose levels, but over time, these metrics declined and aligned with those who experienced successful surgical outcomes. The treatment involved weekly injections that mimic natural incretin hormones, which help lower blood sugar, slow digestion, and promote satiety.
This research fills a crucial knowledge gap regarding the role of GLP-1 RAs in primary prevention of cardiovascular events post-bariatric surgery. While the findings are promising, the study's limitations include a small sample size, and further extensive clinical trials are necessary to validate these results and determine optimal timing for intervention.
The study underscores the potential of combining pharmacotherapy with surgical approaches to optimize long-term health outcomes for individuals battling obesity and diabetes. As obesity rates continue to rise globally, integrating these treatments could become a key strategy in reducing cardiovascular risks associated with obesity and metabolic disorders.
Source: medicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into Astrocytes and Their Crucial Role in Brain Function
New research uncovers the active and complex role of astrocytes in brain function, challenging traditional views and highlighting their importance in neurophysiology and potential in treating neurodegenerative conditions.
Can Asthma Be Predicted? Understanding Early Warning Signs and Risk Factors
Discover how early signs, family history, and predictive tools can help identify children at risk of developing asthma, enabling timely intervention and better management.
New Insights into Mitochondrial Dysfunction's Role in Alzheimer’s Disease Progression and Therapy
Recent Mayo Clinic research highlights mitochondrial complex I dysfunction as a key factor in Alzheimer's disease, opening new paths for early intervention and personalized treatment strategies.
UK Mothers Highlight Lack of Support During Down Syndrome Prenatal Screening Process
A UK study reveals significant gaps in support and information provided to expectant mothers during Down syndrome prenatal screening, highlighting the need for improved patient-centered care and communication.